Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1100570

The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis


Tran, Tanja; Šterclová, Martina; Mogulkoc, Nesrin; Lewandowska, Katarzyna; Müller, Veronika; Hájková, Marta; Kramer R, Mordechai; Jovanović, Dragana; Tekavec-Trkanjec, Jasna; Studnicka, Michael 1 et al.
The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis // Respiratory research, 21 (2020), 1; 104354, 9 doi:10.1186/s12931-019-1271-z (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1100570 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis

Autori
Tran, Tanja ; Šterclová, Martina ; Mogulkoc, Nesrin ; Lewandowska, Katarzyna ; Müller, Veronika ; Hájková, Marta ; Kramer R, Mordechai ; Jovanović, Dragana ; Tekavec-Trkanjec, Jasna ; Studnicka, Michael 1 ; Stoeva, Natalia ; Hejduk, Karel ; Dušek, Ladislav ; Suissa, Samy ; Vašáková, Martina ; EMPIRE registry

Izvornik
Respiratory research (1465-9921) 21 (2020), 1; 104354, 9

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
idiopathic pulmonary fibrosis, survival

Sažetak
Background: Several registries of idiopathic pulmonary fibrosis (IPF) have been established to better understand its natural history, though their size and duration of follow-up are limited. Here, we describe the large European MultiPartner IPF Registry (EMPIRE) and validate predictors of long-term survival in IPF. Methods: The multinational prospective EMPIRE registry enrolled IPF patients from 48 sites in 10 Central and Eastern European countries since 2014. Survival from IPF diagnosis until death was estimated, accounting for left-truncation. The Cox proportional hazards regression model was used to estimate adjusted hazard ratios (HR) of death for prognostic factors, using restricted cubic splines to fit continuous factors. Results: The cohort included 1620 patients (mean age at diagnosis 67.6 years, 71% male, 63% smoking history), including 75% enrolled within 6 months of diagnosis. Median survival was 4.5 years, with 45% surviving 5 years post- diagnosis. Compared with GAP stage I, mortality was higher with GAP stages II (HR 2.9 ; 95% CI: 2.3-3.7) and III (HR 4.0 ; 95% CI: 2.8-5.7) while, with redefined cut-offs, the corresponding HRs were 2.7 (95% CI: 1.8- 4.0) and 5.8 (95% CI: 4.0-8.3) respectively. Mortality was higher with concurrent pulmonary hypertension (HR 2.0 ; 95% CI: 1.5-2.9) and lung cancer (HR 2.6 ; 95% CI: 1.3-4.9). Conclusions: EMPIRE, one of the largest long- term registries of patients with IPF, provides a more accurate confirmation of prognostic factors and co-morbidities on longer term five- year mortality. It also suggests that some fine-tuning of the indices for mortality may provide a more accurate long-term prognostic profile for these patients.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
KBC Split,
Medicinski fakultet, Split

Profili:

Avatar Url Jasna Tekavec Trkanjec (autor)

Avatar Url Suzana Mladinov (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Tran, Tanja; Šterclová, Martina; Mogulkoc, Nesrin; Lewandowska, Katarzyna; Müller, Veronika; Hájková, Marta; Kramer R, Mordechai; Jovanović, Dragana; Tekavec-Trkanjec, Jasna; Studnicka, Michael 1 et al.
The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis // Respiratory research, 21 (2020), 1; 104354, 9 doi:10.1186/s12931-019-1271-z (međunarodna recenzija, članak, znanstveni)
Tran, T., Šterclová, M., Mogulkoc, N., Lewandowska, K., Müller, V., Hájková, M., Kramer R, M., Jovanović, D., Tekavec-Trkanjec, J. & Studnicka, M. (2020) The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respiratory research, 21 (1), 104354, 9 doi:10.1186/s12931-019-1271-z.
@article{article, author = {Tran, Tanja and \v{S}terclov\'{a}, Martina and Mogulkoc, Nesrin and Lewandowska, Katarzyna and M\"{u}ller, Veronika and H\'{a}jkov\'{a}, Marta and Kramer R, Mordechai and Jovanovi\'{c}, Dragana and Tekavec-Trkanjec, Jasna and Studnicka, Michael 1 and Stoeva, Natalia and Hejduk, Karel and Du\v{s}ek, Ladislav and Suissa, Samy and Va\v{s}\'{a}kov\'{a}, Martina}, year = {2020}, pages = {9}, DOI = {10.1186/s12931-019-1271-z}, chapter = {104354}, keywords = {idiopathic pulmonary fibrosis, survival}, journal = {Respiratory research}, doi = {10.1186/s12931-019-1271-z}, volume = {21}, number = {1}, issn = {1465-9921}, title = {The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis}, keyword = {idiopathic pulmonary fibrosis, survival}, chapternumber = {104354} }
@article{article, author = {Tran, Tanja and \v{S}terclov\'{a}, Martina and Mogulkoc, Nesrin and Lewandowska, Katarzyna and M\"{u}ller, Veronika and H\'{a}jkov\'{a}, Marta and Kramer R, Mordechai and Jovanovi\'{c}, Dragana and Tekavec-Trkanjec, Jasna and Studnicka, Michael 1 and Stoeva, Natalia and Hejduk, Karel and Du\v{s}ek, Ladislav and Suissa, Samy and Va\v{s}\'{a}kov\'{a}, Martina}, year = {2020}, pages = {9}, DOI = {10.1186/s12931-019-1271-z}, chapter = {104354}, keywords = {idiopathic pulmonary fibrosis, survival}, journal = {Respiratory research}, doi = {10.1186/s12931-019-1271-z}, volume = {21}, number = {1}, issn = {1465-9921}, title = {The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis}, keyword = {idiopathic pulmonary fibrosis, survival}, chapternumber = {104354} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font